$5.9 Billion is the total value of ARMISTICE CAPITAL, LLC's 139 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CPRX | CATALYST PHARMACEUTICALS INC | $53,000,000 | -7.8% | 10,000,000 | 0.0% | 0.90% | -12.7% | |
| UNH | UNITEDHEALTH GROUP INC | $39,074,000 | -2.4% | 100,000 | 0.0% | 0.66% | -7.7% | |
| VYGR | VOYAGER THERAPEUTICS INC | $9,773,000 | -36.3% | 3,716,000 | 0.0% | 0.17% | -39.6% | |
| TENAX THERAPEUTICS INC | $3,575,000 | -14.9% | 2,019,995 | 0.0% | 0.06% | -18.7% | ||
| BCTXW | BRIACELL THERAPEUTICS CORP*w exp 02/24/202 | $1,781,000 | +163.9% | 375,000 | 0.0% | 0.03% | +150.0% | |
| GROMW | GROM SOCIAL ENTERPRISES INC*w exp 06/17/202 | $795,000 | +10.0% | 723,000 | 0.0% | 0.01% | 0.0% | |
| MDGSW | MEDIGUS LTD*w exp 07/23/202 | $745,000 | +3.5% | 1,285,715 | 0.0% | 0.01% | 0.0% | |
| DBGIW | DIGITAL BRANDS GROUP INC*w exp 05/01/202 | $557,000 | -54.7% | 722,890 | 0.0% | 0.01% | -59.1% | |
| GROYWS | GOLD ROYALTY CORP*w exp 99/99/999 | $448,000 | -4.7% | 448,000 | 0.0% | 0.01% | 0.0% | |
| NLSPW | NLS PHARMACEUTICS LTD*w exp 09/25/202 | $413,000 | -8.6% | 500,000 | 0.0% | 0.01% | -12.5% | |
| GMVDW | G MED INNOVATIONS HLDGS LTD*w exp 06/30/202 | $394,000 | -61.9% | 1,000,000 | 0.0% | 0.01% | -63.2% | |
| SYTAW | SIYATA MOBILE INC*w exp 09/24/202 | $102,000 | -85.3% | 150,000 | 0.0% | 0.00% | -83.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC | 30 | Q3 2023 | 2.7% |
| SPDR S&P 500 ETF TR | 28 | Q3 2023 | 29.5% |
| MADRIGAL PHARMACEUTICALS INC | 27 | Q3 2023 | 2.9% |
| VANDA PHARMACEUTICALS INC | 26 | Q3 2021 | 9.4% |
| REGENERON PHARMACEUTICALS | 25 | Q3 2023 | 3.2% |
| ENERGIZER HLDGS INC NEW | 22 | Q2 2023 | 3.7% |
| ANTARES PHARMA INC | 21 | Q3 2020 | 6.6% |
| INCYTE CORP | 21 | Q3 2023 | 2.8% |
| VOYAGER THERAPEUTICS INC | 21 | Q3 2023 | 2.0% |
| BLUEBIRD BIO INC | 20 | Q4 2021 | 1.8% |
View ARMISTICE CAPITAL, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Avalo Therapeutics, Inc. | June 28, 2023 | 588,850 | 4.7% |
| Addex Therapeutics Ltd. | February 16, 2023 | 675,295 | 5.0% |
| Arcadia Biosciences, Inc. | February 14, 2023 | 2,675,409 | 10.0% |
| Avinger Inc | February 14, 2023 | 789,400 | 10.0% |
| Baudax Bio, Inc. | February 14, 2023 | 1,165,709 | 5.0% |
| BIORA THERAPEUTICS, INC. | February 14, 2023 | 12,989,648 | 5.7% |
| Bit Digital, Inc | February 14, 2023 | 3,161,889 | 3.7% |
| Bruush Oral Care Inc. | February 14, 2023 | 1,122,922 | 10.0% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Clarus Therapeutics Holdings, Inc. | February 14, 2023 | 2,732,169 | 5.0% |
View ARMISTICE CAPITAL, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View ARMISTICE CAPITAL, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.